Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Sep:941:177-84.
doi: 10.1111/j.1749-6632.2001.tb03721.x.

The role for interleukin-12 therapy of cutaneous T cell lymphoma

A H Rook  1 , M H Zaki, M Wysocka, G S Wood, M Duvic, L C Showe, F Foss, M Shapiro, T M Kuzel, E A Olsen, E C Vonderheid, R Laliberte, M L Sherman
Affiliations
Clinical Trial

The role for interleukin-12 therapy of cutaneous T cell lymphoma

A H Rook et al. Ann N Y Acad Sci. 2001 Sep.

Abstract

Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

PubMed Disclaimer

Publication types

MeSH terms